Application of machine learning methods to pathogen safety evaluation in biological manufacturing processes
- PMID: 33527773
- PMCID: PMC8365771
- DOI: 10.1002/btpr.3135
Application of machine learning methods to pathogen safety evaluation in biological manufacturing processes
Abstract
The production of recombinant therapeutic proteins from animal or human cell lines entails the risk of endogenous viral contamination from cell substrates and adventitious agents from raw materials and environment. One of the approaches to control such potential viral contamination is to ensure the manufacturing process can adequately clear the potential viral contaminants. Viral clearance for production of human monoclonal antibodies is achieved by dedicated unit operations, such as low pH inactivation, viral filtration, and chromatographic separation. The process development of each viral clearance step for a new antibody production requires significant effort and resources invested in wet laboratory experiments for process characterization studies. Machine learning methods have the potential to help streamline the development and optimization of viral clearance unit operations for new therapeutic antibodies. The current work focuses on evaluating the usefulness of machine learning methods for process understanding and predictive modeling for viral clearance via a case study on low pH viral inactivation.
Keywords: biological manufacturing process; low pH viral inactivation; machine learning; monoclonal antibody; pathogen safety.
© 2021 Bayer US. Biotechnology Progress published by Wiley Periodicals LLC on behalf of American Institute of Chemical Engineers.
Conflict of interest statement
A provisional patent application has already been filed to protect the intellectual property.
Figures









References
-
- Schwantes A, Specht R, Chen Q. Proceedings of the 2017 viral clearance symposium, session 4: submission strategies. PDA J Pharm Sci Technol. 2018;72(5):498‐510. - PubMed
-
- Galbraith D. ICH Q5A. ICH Quality Guidelines 2017. 311‐335. https://onlinelibrary.wiley.com/doi/abs/10.1002/9781118971147.ch10 - DOI
-
- ASTM E2888‐12, Standard Practice for Process for Inactivation of Rodent Retrovirus by pH. West Conshohocken, PA2012.
-
- PAT — a framework for innovative pharmaceutical development, manufacturing, and quality assurance In: FDA, ed2004.
-
- Q8(R2) pharmaceutical development. In: FDA, ed2009.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources